Skip to main content

Table 1 Dosing of ParvOryx in the current trial

From: A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

Total dose Study Time Individual dose and route of administration Duration
Dose level 1 (1 subject)
 1E09 pfu Day 1–4 1E08 pfu, intravenous infusion 2 h
Day 7 6E08 pfu, intrametastatic injection As slowly as feasible
Dose level 2 (3 subjects)
 5E09 pfu Day 1–4 5E08 pfu, intravenous infusion 2 h
Day 7 or 10 or 14 3E09 pfu, intrametastatic injection As slowly as feasible
Dose level 3 (3 subjects)
 1E10 pfu Day 1–4 1E09 pfu, intravenous infusion 2 h
Day 7 or 10 or 14 6E09 pfu, intrametastatic injection As slowly as feasible